Author Correction: Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis
A correction to this article has been published and is linked from the HTML version of this paper. The error has been fixed in the paper.
Main Authors: | Ghaith Aljayyoussi, Hayley E. Tyrer, Louise Ford, Hanna Sjoberg, Nicolas Pionnier, David Waterhouse, Jill Davies, Joanne Gamble, Haelly Metuge, Darren A. N. Cook, Andrew Steven, Raman Sharma, Ana F. Guimaraes, Rachel H. Clare, Andrew Cassidy, Kelly L. Johnston, Laura Myhill, Laura Hayward, Samuel Wanji, Joseph D. Turner, Mark J. Taylor, Stephen A. Ward |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2018-01-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-018-19723-1 |
Similar Items
-
Short-course, high-dose rifampicin achieves wolbachia depletion predictive of curative outcomes in preclinical models of lymphatic filariasis and onchocerciasis
by: Aljayyoussi, G, et al.
Published: (2017) -
Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis
by: Taylor, MJ, et al.
Published: (2019) -
A murine macrofilaricide pre-clinical screening model for onchocerciasis and lymphatic filariasis
by: Alice Halliday, et al.
Published: (2014-10-01) -
Anti-Wolbachia therapy for onchocerciasis & lymphatic filariasis: current perspectives
by: Wan Sulaiman, Wan Aliaa, et al.
Published: (2019) -
Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts of onchocerciasis and lymphatic filariasis
by: Kelly L. Johnston, et al.
Published: (2014-12-01)